Novavax Scientific Leadership to Present RSV Maternal Immunization Program Phase 3 Data and Participate in Panel on COPD at World Vaccine Congress

    NEXT STORY
    Guardant Health Announces Commercial Payer Progress with more than 150 Million Lives Covered for Guardant360
    PREV STORY
    OSE Immunotherapeutics Announces Issuance of Canadian Patent and Notice of Allowance of U.S. Patent Protecting CD28-Antagonist Immunotherapy FR104
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Novavax Scientific Leadership to Present RSV Maternal Immunization Program Phase 3 Data and Participate in Panel on COPD at World Vaccine Congress

    NEXT STORY
    Guardant Health Announces Commercial Payer Progress with more than 150 Million Lives Covered for Guardant360
    PREV STORY
    OSE Immunotherapeutics Announces Issuance of Canadian Patent and Notice of Allowance of U.S. Patent Protecting CD28-Antagonist Immunotherapy FR104
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Applied Therapeutics, Inc. Announces Upsizing and Pricing of Public Offering of 2,741,489 Shares of Common Stock

    author_avatar
    NASDAQ Market News

    Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia

    author_avatar
    NASDAQ Market News

    Novartis verzeichnet ein weiteres starkes Quartal mit zweistelligem Umsatz-wachstum und höherer Kerngewinnmarge1; Umsatz- und Gewinnerwartung für 2019 angehoben; US-Einführung von Beovu

    author_avatar
    NASDAQ Market News